Deedwania P, et al. - A meta-analysis based on age and chronic kidney disease status was performed to assess the efficacy of olmesartan-based monotherapy vs combination therapy in hypertension. Researchers here recognized that olmesartan medoxomil (OM) single-pill dual-combination therapy was well tolerated and more effective in lowering blood pressure (BP) than OM monotherapy, enabling more patients to achieve guideline-recommended BP goals with a preferable safety profile.